GlassScriptPhysician profile
Erasme Coly
NPI 1083745335
$7,397.05
in general payments reported to CMS, 2019-2025
21 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $546 · 2021: $418 · 2022: $1,768 · 2023: $313 · 2024: $2,626 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Travel and Lodging: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.16 |
| Travel and Lodging | $1,473.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,568.44 | 2021-2024 | Micra, Selectsecure |
| Biotronik INC. | $1,011.05 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $507.14 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $495.80 | 2019-2025 | |
| Abbott Laboratories | $368.21 | 2020-2025 | Xience Skypoint, Dragonfly Opstar, Xience Sierra |
| Janssen Pharmaceuticals, INC | $345.16 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $204.64 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.85 | 2019-2021 | |
| Pfizer INC. | $148.43 | 2019-2025 | |
| Cardiovascular Systems INC. | $122.36 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $122.34 | 2023-2025 | Eliquis, Camzyos |
| Amgen INC. | $64.57 | 2019-2021 | |
| Daiichi Sankyo INC. | $62.35 | 2020-2021 | |
| Boston Scientific Corporation | $40.12 | 2021-2025 | Eluvia |
| Medtronic Vascular, INC. | $25.71 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocompatibles, INC. | $24.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.05 | 2023 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $21.53 | 2020 | |
| Irhythm Technologies, INC. | $15.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erasme Coly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.